

UK Lighthouse Labs Network



Alderley Park

Epidemiological Investigation of New SARS-CoV-2 Variant of Concern 202012/01 in England

Author List

Alfredo Maria Gravagnuolo,^{1,†} Layla Faqih,^{1,†,*} Cara Cronshaw,² Jackie Wynn,¹ Lewis Burglin,¹ Paul Klapper^{1,3,†} and Mark Wigglesworth.^{1,†,*}

[†]Contributed equally

^{*}Corresponding authors

For queries relating to this document, please contact: layla.faqih@md.catapult.org.uk; mark.wigglesworth@md.catapult.org.uk.

Affiliations

1 Medicines Discovery Catapult, Lighthouse Labs, Alderley Park, Mereside, Alderley Edge, Cheshire, SK10 4TG, United Kingdom.

2 Department of Health & Social Care, Lighthouse Labs, Alderley Park, Mereside, Alderley Edge, Cheshire, SK10 4TG, United Kingdom.

3 The University of Manchester, Oxford Rd, Manchester, M13 9PL, United Kingdom.

Abstract

Lighthouse Labs network tests for the presence of RNA of SARS-CoV-2, the causative agent of COVID-19. The ThermoFisher TaqPath assay targets three regions of SARS-CoV-2; ORF1ab, N and S-genes. The assay identified a drop in S-gene target detection among positive samples due to the circulation of a new SARS-CoV-2 Variant of Concern (VOC) designated as 202012/01. By end of December 2020, 60% of daily positive test results at Alderley Park Lighthouse Labs, were linked to the new Variant of Concern. This timeline view identifies the rapid spread of the variant across the country.

Keywords: COVID-19; testing; England; S-gene target failure; variants; spread.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

INTRODUCTION

Alderley Park (AP) Lighthouse Lab (LHL) tests for the presence of RNA of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19).

The laboratory uses the ThermoFisher TaqPath™ COVID-19 test, for real-time reverse transcription polymerase chain reaction (RT-qPCR) detection of SARS-CoV-2 in nose and throat swabs. The assay contains three primer/probe sets specific to different SARS-CoV-2 genomic regions, and the RNA of the bacteriophage MS2 is used as an internal control molecule to monitor potential sample inhibition.

As viruses can show substantial genetic variability, which can over time result in mismatches between the primer/probe and the target sequences, the assay targets three genomic sequences (ORF1ab, N and S) to improve reliability of detection of SARS-Cov-2.

An increase in the number of positive samples with lack of S gene amplification was noted in late November. As a percentage of positive samples from the LH laboratories are referred to the Wellcome Sanger Laboratory at Cambridge (UK) for whole genome sequencing we were able to identify that the samples with failure to detect S gene amplification were due to a deletion of six nucleotides in the S-gene, which results in the loss of two amino acids of the Spike protein at positions 69 and 70 ($\Delta 69-70$); (PHE, 2020). Data from the national network of high throughput testing facilities has been utilised to demonstrate the localisation and rapid temporal spread of this variant. Samples for SARS-CoV-2 detection are derived from any area of the UK. A distribution network load balances sample distribution to one of the five major UK centres on a daily basis, analysis of samples arriving in one of these facilities can provide information on the distribution of infection within the whole of England.

SARS-CoV-2 targets in strong positive test results

Five-day rolling rate per total number of strong positives by date of test result




Figure 1. TaqPath™ COVID 19 Assay, S-gene detection in comparison to ORF1ab and N-gene.

RESULTS

The impact of the new variant on the diagnostic testing

The proportion in England of positive specimens tested using the ThermoFisher TaqPath™ COVID-19 assay with failure of S-gene target detection increased rapidly in December 2020 rising to over 70% of strong positive test results detected within the facility at the beginning of January 2021 (**Figure 1**, five-day rolling rate). The failure of S-gene detection does not significantly alter the clinical validity of the test result as detection of the alternate target (ORF1Ab and N) has remained robust.

Epidemiological clusters associated with S-gene target failure

Samples tested at Alderley Park Lighthouse Labs, from the 1st to the 21st of December 2020, were collected and linked to geographical area within England (**Table 1**; **Figure 2**; **supporting information video map**).

The distribution of S-gene target failure cases shows a relatively higher burden in London, East-South East, parts of the North West, South west regions and West Midlands. While the sample collection and distribution network load balancing does not allow that the same number of samples is delivered consistently from each geographic area the data does provide some indication on the national geographic spread of the variant with time. As sample numbers were not collected equally from each region a low detection rate cannot be considered conclusive proof of the variant not being present. However, when viewed as a percentage of samples the data clearly shows a geographical bias within the overall sample set. Clustering was observed around population centres of London, cities of the coastal South, Manchester, Birmingham, Bristol and Liverpool (**Figure 2**).

Areas with the highest incidence in our study also coincide with areas now reporting high levels of patient hospitalisation (NHS, 2021). The timeline view identifies the rapid spread of this in high population areas across the country and reinforces the necessity of subsequent National lockdown to contain spread of the variant.

Table 1. Geographical origins in England of the new cases of S-gene target failure at Alderley Park Lighthouse Labs, in the assessed time ranges.

Region – Data from 1 st - 21 st Dec	[%]	Region – Data from 1 st - 30 th Dec	[%]
London	38.8	London	27.6
South East	30.1	South East	24.3
North West	9.9	North West	22.5
East of England	7.1	East of England	5.1
South West	6.7	South West	9.9
West Midlands	4.6	West Midlands	7.7
East Midlands	2.1	East Midlands	1.6
Yorkshire and the Humber	0.7	Yorkshire and the Humber	1.2
North East	0.1	North East	0.1
Total	100	Total	100




Figure 2. Map of S-gene detection failure, associated with the new SARS-CoV-2 variant. Data collected at Alderley Park, Lighthouse Labs, from 1st to 21st of December 2020.

Molecular analysis of Virus strains associated with S-gene target failure – Pending Work

Samples of extracted RNA tested at Alderley Park, Lighthouse Labs, were sequenced at the Wellcome Sanger Institute, Cambridge, UK.

At the beginning of December, the Sanger Institute has identified and sequenced a significant number of samples with negative S-gene target detection by the TaqPath™ COVID 19 Kit, but positive for the ORF1ab and N-gene targets. Analysis showed that Spike protein mutations characteristic of VOC 202012/01 were present in these S-gene target detection failure cases indicating the predictive nature of our S-gene target detection failure for the presence of the VOC. However, ongoing molecular surveillance is needed to ensure identify mutations, which are currently preventing amplification of the S-gene target, remain characteristic of the VOC.

CONCLUSIONS

The failure of S-gene target detection is related to the recent emergence of the new variant of concern. Geographical regions affected by VOC 202012/01 are clearly illustrated by the absence of S gene detection in the TaqPath assay used in our study, which coincide with areas now reporting high levels of patient hospitalisation.

Ongoing molecular monitoring will be needed to ensure that no further new S gene variants are co-emerging with VOC 202012/01.

The value of high throughput testing and use of multitarget PCR technology in early detection of the emergence of viral variants is illustrated in the present data.

EXPERIMENTAL SECTION

Sample acquisition.

Samples delivered to the LH laboratory, Alderley Park, can be derived from any area of the UK. A distribution network load balances sample distribution to one of the five major UK centres daily. Sample tracking data is held centrally in a proprietary data base (Edge; Department of Health and Social Care, UK).

SARS-CoV-2 Testing.

Nose and throat swab samples in virus transport medium collected at a variety of test centres and home self-collected samples shipped to Alderley Park were extracted using the MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit (ThermoFisher, Warrington, UK) and Kingfisher Flex extraction platform (ThermoFisher). PCR amplification used the TaqPath™ COVID-19 Combo Kit (ThermoFisher) and 384 well format on Quantstudio Flex 7 System and UgenTec-FastFinder PCR analysis software (Eugentec, Hasselt, Belgium). S-gene target detection failure was defined where: ORF1ab Cq value lower than 31.6; N-gene Cq lower than 30.1; S-gene target was not amplified. Those cases were linked to the new SARS-CoV-2 variant.

Geographical origins of samples.

Subject postal district, (**Figure 2** and **supporting information video map**), and test region (**Table 1**), were extracted via interrogation of the Edge data.

Data analysis.

Figure 1. December data available in **Table 3** (last column) showing daily figures and five-day rolling rate of S-gene Target Failure per total number of strong positive test results. The same method was used for the five-day rolling rate the ORF1ab and N-gene target failure per total number of strong positive test results.

Figure 2 and **supporting information video map.** Locations displayed on the Map resulted from subject postal district and date tested. Cases displayed on the Map were accumulated over the assessed period in chronological order generating a heat map. Data were limited to numbers (counts) of cases from Alderley Park data set, and not normalised by the total number of positive test results. *Heat map:* indicative density of cases of S-gene target failure in the areas highlighted by colours (see colour bar). *Map coverage:* 98% of cases listed in **Table 3** under column “cases of S-gene target failure” were matched with locations in the assessed time range. *Accuracy:* 95% of matched locations were plotted with high confidence. As a result of map coverage and accuracy, ~93% of total cases in **Table 3** were linked to their locations and indicated on the heat map.

Table 1. Geographical origins of new cases of S-gene target failure, identified at Alderley Park Lighthouse Labs from 1st – 21st December 2020, were shown as fractions of total cases of S-gene target failure in the same time range. For comparison, a longer assessment period, 1st - 30th December, was shown.

Table 2. Cq cut-off values for strong positive test results in this study.

Conditions for strong positive test results at least two target amplicons		
ORF1ab Cq < 31.6	N gene Cq < 30.1	S gene Cq < 31.6

Table 3. Raw data of December, Alderley Park, Lighthouse Labs.

Date tested at Alderley Park Lighthouse Labs	TOT numbers of positive Test Results (TRs)	TOT number of strong positive TRs (two or three targets strong positives)	Cases of three detected SARS-CoV-2 targets in strong positive TRs	Day rate per total number of strong positive TRs	Cases of ORF1ab target failure in strong positive TRs (N and S-genes targets strong positives)	Cases of N-gene target failure in strong positive TRs (ORF1ab and S-gene targets strong positives)	Cases of S-gene target failure in strong positive TRs (ORF1ab and N-gene target strong positives)	Five-day rolling average	Day rate per total number of strong positive TRs	Five-day rolling rate per total number of strong positive TRs
27/11/2020	3195	2837	2571	90.6%	1	7	258		9.1%	
28/11/2020	2552	2258	1972	87.3%	0	3	283	by date of test result	12.5%	by date of test result
29/11/2020	1912	1732	1599	92.3%	0	3	130		7.5%	
30/11/2020	3076	2801	2445	87.3%	0	12	344		12.3%	
01/12/2020	2917	2662	2305	86.6%	0	9	348	273	13.1%	11.1%
02/12/2020	2475	2280	2144	94.0%	0	3	133	248	5.8%	10.6%
03/12/2020	2278	2102	1959	93.2%	0	9	134	218	6.4%	9.4%
04/12/2020	1814	1664	1540	92.5%	0	7	117	215	7.0%	9.3%
05/12/2020	2928	2697	2481	92.0%	0	12	204	187	7.6%	8.2%
06/12/2020	2350	2147	1562	72.8%	0	9	576	233	26.8%	10.7%
07/12/2020	1832	1706	1279	75.0%	1	9	417	290	24.4%	14.0%
08/12/2020	2174	2012	1763	87.6%	0	6	243	311	12.1%	15.2%
09/12/2020	3968	3669	2464	67.2%	0	10	1195	527	32.6%	21.5%
10/12/2020	4537	4222	3002	71.1%	0	11	1209	728	28.6%	26.5%

11/12/2020	4205	3954	3027	76.6%	1	9	917	796	23.2%	25.6%
12/12/2020	4538	4281	2840	66.3%	1	9	1431	999	33.4%	27.5%
13/12/2020	4725	4416	2689	60.9%	0	16	1711	1293	38.7%	31.5%
14/12/2020	5383	5073	3367	66.4%	0	21	1685	1391	33.2%	31.7%
15/12/2020	5867	5522	2694	48.8%	0	23	2805	1710	50.8%	36.8%
16/12/2020	5230	4912	2706	55.1%	0	15	2191	1965	44.6%	40.6%
17/12/2020	5891	5614	2765	49.3%	0	20	2829	2244	50.4%	43.9%
18/12/2020	4768	4523	2260	50.0%	0	17	2246	2351	49.7%	45.8%
19/12/2020	5289	4984	2420	48.6%	1	16	2547	2524	51.1%	49.4%
20/12/2020	3084	2915	2024	69.4%	0	7	884	2139	30.3%	46.6%
21/12/2020	4225	4002	2210	55.2%	0	12	1780	2057	44.5%	46.7%
22/12/2020	3638	3439	1942	56.5%	0	20	1477	1787	42.9%	45.0%
23/12/2020	3694	3452	1934	56.0%	0	24	1494	1636	43.3%	43.5%
24/12/2020	4098	3781	2202	58.2%	0	14	1565	1440	41.4%	40.9%
25/12/2020	4276	3992	2130	53.4%	0	9	1853	1634	46.4%	43.8%
26/12/2020	4808	4504	2152	47.8%	0	16	2336	1745	51.9%	45.5%
27/12/2020	4898	4569	1743	38.1%	0	21	2805	2011	61.4%	49.5%
28/12/2020	3778	3500	1748	49.9%	0	27	1725	2057	49.3%	50.5%
29/12/2020	3407	3169	1403	44.3%	0	13	1753	2094	55.3%	53.1%
30/12/2020	5667	5293	2251	42.5%	0	22	3020	2328	57.1%	55.3%
31/12/2020	6842	6307	1966	31.2%	0	17	4324	2725	68.6%	59.7%
Grand total (December)	125584	117363	68972		4	433	47954			
Rate (December)		100%	58.77%		0.0%	0.37%	40.86%			
Chart							Figure 2	Figure 1		

REFERENCES

- Bal, A. *et al.* (2021). Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralisation and commercial assays. *Clinical Microbiology and Infection*, <https://doi.org/10.1016/j.cmi.2021.01.003>.
- Public Health England (PHE), (2020). Investigation of novel SARS-COV-2 variant. Variant of Concern 202012/01. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf , (Accessed 14/01/2021)
- Public Health England (PHE), (2020). Investigation of novel SARS-COV-2 variant. Variant of Concern 202012/01. Technical briefing 2. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948152/Technical_Briefing_VOC202012-2_Briefing_2_FINAL.pdf , (Accessed 14/01/2021)
- National Health Service (NHS), (2021). COVID-19 Hospital Activity. Available at: <https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/> , (Accessed 14/01/2021)

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

ACKNOWLEDGMENTS

COVID-19 National Testing Programme

Health Research Authority, National Health Service (**HRA-NHS**), United Kingdom.

Medicines Discovery Catapult, Lighthouse Labs, Alderley Park (**MDC-LHL-AP**), United Kingdom: Simon Chapman, Andrzej Rutkowski, Helen Hind, Salina Hussain, Nathan Hayes, Thomas Ingram, Farah Tahmasebi, Sul Mulroy, Maged Taema, Kirsten Hobby, Amir Mossanen-Parsi.

The University of Manchester, United Kingdom (**UOM**).

Department of Health & Social Care, United Kingdom (**DHSC**).

Wellcome Sanger Institute, United Kingdom (**WSI**): Jeffrey Barrett.

Astra Zeneca, United Kingdom (**AZ**): David Murray.

WEB

<https://lighthouselabsalderleypark.org.uk/>

Published: January 2021.

Version 1, release date 07/01/2021 (submitted).

Version 1.1, release date 14/01/2021 (submitted).